Gładyś A, Kozak S, Wdowiak K, Winder M, Chudek J. Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature. World J Clin Cases 2021; 9(3): 748-757 [PMID: 33553416 DOI: 10.12998/wjcc.v9.i3.748]
Corresponding Author of This Article
Aleksandra Gładyś, N/A, N/A, Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Reymonta 8, Katowice 40-027, Woj. śląskie, Poland. aleksandragladys@outlook.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 26, 2021; 9(3): 748-757 Published online Jan 26, 2021. doi: 10.12998/wjcc.v9.i3.748
Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature
Aleksandra Gładyś, Sylwia Kozak, Kamil Wdowiak, Mateusz Winder, Jerzy Chudek
Aleksandra Gładyś, Sylwia Kozak, Kamil Wdowiak, Mateusz Winder, Jerzy Chudek, Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Katowice 40-027, Woj. śląskie, Poland
Author contributions: Gładyś A and Kozak S drafted this paper; Wdowiak K and Chudek J made critical revisions; Winder M selected images; Chudek J made final verification.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Aleksandra Gładyś, N/A, N/A, Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences, Medical University of Silesia in Katowice, Reymonta 8, Katowice 40-027, Woj. śląskie, Poland. aleksandragladys@outlook.com
Received: November 5, 2020 Peer-review started: November 5, 2020 First decision: November 23, 2020 Revised: December 2, 2020 Accepted: December 16, 2020 Article in press: December 16, 2020 Published online: January 26, 2021 Processing time: 75 Days and 15.1 Hours
Core Tip
Core Tip: Post-transplant lymphoproliferative disease (PTLD) is a heterogeneous group of diseases in transplantated patients related to immunosuppression regimen, T-cell depletion and Epstein-Barr virus infection. Immunochemotherapy (ICHT) increases already high incidence of bacterial infections in transplanted patients related to the immunosuppression therapy. We report the successful management of two solid organ transplanted patients with PTLD and urinary and pulmonary tract infections infections during ICTH that developed regardless of the reduction of immunosuppression therapy, doses of chemotherapeutics and GCS-F used in the prevention of neutropenic fever. We show that all these interventions may be insufficient to prevent infectious complications, but they are manageable.
